Zhejiang DiAn Diagnostics Co - Asset Resilience Ratio
Zhejiang DiAn Diagnostics Co (300244) has an Asset Resilience Ratio of 3.61% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 300244 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how Zhejiang DiAn Diagnostics Co's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 300244 asset base.
Liquid Assets Composition Over Time
This chart breaks down Zhejiang DiAn Diagnostics Co's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Zhejiang DiAn Diagnostics Co long-term investment allocation to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥508.66 Million | 3.61% |
| Total Liquid Assets | CN¥508.66 Million | 3.61% |
Asset Resilience Insights
- Limited Liquidity: Zhejiang DiAn Diagnostics Co maintains only 3.61% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Zhejiang DiAn Diagnostics Co Industry Peers by Asset Resilience Ratio
Compare Zhejiang DiAn Diagnostics Co's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
LONZA GROUP UNSP.ADR 1/10
F:LO3A |
Diagnostics & Research | 3.04% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Eurofins-Cerep SA
PA:ALECR |
Diagnostics & Research | 13.42% |
|
Gencurix Inc
KQ:229000 |
Diagnostics & Research | 4.01% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Annual Asset Resilience Ratio for Zhejiang DiAn Diagnostics Co (2019–2025)
The table below shows the annual Asset Resilience Ratio data for Zhejiang DiAn Diagnostics Co.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 3.08% | CN¥444.45 Million ≈ $65.04 Million |
CN¥14.42 Billion ≈ $2.11 Billion |
+0.65pp |
| 2024-12-31 | 2.44% | CN¥384.59 Million ≈ $56.28 Million |
CN¥15.79 Billion ≈ $2.31 Billion |
+0.10pp |
| 2023-12-31 | 2.33% | CN¥418.30 Million ≈ $61.21 Million |
CN¥17.94 Billion ≈ $2.63 Billion |
+0.19pp |
| 2022-12-31 | 2.14% | CN¥450.09 Million ≈ $65.86 Million |
CN¥21.06 Billion ≈ $3.08 Billion |
-0.60pp |
| 2021-12-31 | 2.74% | CN¥427.22 Million ≈ $62.52 Million |
CN¥15.59 Billion ≈ $2.28 Billion |
+0.24pp |
| 2020-12-31 | 2.50% | CN¥310.26 Million ≈ $45.40 Million |
CN¥12.40 Billion ≈ $1.81 Billion |
-0.23pp |
| 2019-12-31 | 2.73% | CN¥293.24 Million ≈ $42.91 Million |
CN¥10.75 Billion ≈ $1.57 Billion |
-- |
About Zhejiang DiAn Diagnostics Co
Dian Diagnostics Group Co.,Ltd. provides integrated medical diagnostics solutions with independent diagnostic services in China. The company offers laboratory supplies and kits; AI-assisted digital pathology diagnosis solutions, such as nucleic acid extraction and purification system, automatic liquid-based cytology slide preparation and staining system, digital pathology slide scanner, automated… Read more